Evaluation of new nanotechnology to raise HDL cholesterol level and elucidation of its molecular mechanism

点击翻译按钮获取中文摘要

Raising HDL-cholesterol (C) has emerged as a potential strategy to tackle the residual risk that remains even after lowering LDL-C and triglyceride, in preventing cardiovascular disease. PEGylated and quaternized polyamine nanogel (Q-Nanogel) is a newly synthesized bile salt sequestering agent intended to treat dyslipidemia. We assessed the effects of Nanogel on dyslipidemia and atherosclerosis. Nanogel treatment resulted in a 35% reduction in plasma VLDL/LDL-C levels, a 58% increase in plasma HDL-C levels in C57BL/6J mice. In LDLR-/-mice, atherosclerotic lesion size with Nanogel was reduced by 45% compared to PBS. These data indicate that Nanogel not only decreased VLDL/LDL-C levels but also raised HDL-C levels. Nanogel could be a potential therapeutic candidate to raise HDL-C and the treatment of atherosclerosis.